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Abstract
The impact of antimicrobial resistance on patient outcomes can be
effectively measured only if the appropriateness of the anti-
microbial therapy received is properly measured. Definition of
appropriate therapy should include not only in vitro susceptibility
but also the clinical adequacy of the antibiotic used, taking into
account the pathogen isolated, the site of infection, known
pharmacokinetic and pharmacodynamic properties of the drug, and
dosing. In the absence of these data, the effect of delay or
absence of appropriate therapy in patients infected with resistant
bacterial pathogens is subject to confounding, and the true effect
of resistance on outcomes may be obscured.
Do infections with antibiotic-resistant pathogens yield worse
outcomes than similar infections in similar patients with
susceptible pathogens? The practical importance of knowing
the answer to this question relates both to infection control -
that is, are the considerable resources and inconveniences
required to contain the spread of multi-drug-resistant (MDR)
bacteria justified by reduced morbidity and mortality? - and to
treatment decisions - that is, should empirical antimicrobial
therapy be modified in the face of resistance? A number of
reasons that MDR pathogens may be associated with worse
outcomes can be offered, including increased virulence of
MDR strains of bacteria, inferior therapeutic options for MDR
bacteria owing to restrictions posed by resistance profiles,
and delay in the initiation of appropriate therapy owing to the
resistance. The first reason offered is pathogen-related, the
second and third treatment-related.
In a recent issue of Critical Care, Depuydt and colleagues
addressed this question in a cohort of patients with ventilator-
associated pneumonia (VAP) [1]. In a carefully designed
study using state of the art microbiological and statistical
methods, they found that resistance is not an independent
predictor of 30-day in-hospital mortality. This conclusion,
though reported in the past as well [2], contrasts with those
of several recent studies that found that antimicrobial resis-
tance does independently predict poor outcomes in VAP
[3-5]. In light of Depuydt and colleagues’ findings, should we
revise our perceptions regarding the deleterious effects of
multi-drug resistance on patient outcomes?
Leaving aside for a moment the conclusions of the authors,
let us consider whether the data collected offer us the oppor-
tunity to compare infections caused by MDR versus non-
MDR pathogens. Regarding the putative pathogen-related
cause for worse outcomes - increased virulence of MDR
pathogens compared with their non-MDR counterparts - we
can draw no conclusions from this study. In order to compare
virulence, the study would have to include data on the
bacteria themselves. In the absence of these data, we might
be able to infer something about the bacteria if presented
with a head-to-head comparison of a specific pathogen-
related infection, that is, VAP caused by MDR Pseudomonas
versus VAP caused by non-MDR Pseudomonas. The study
design, which compares cases of VAP caused by MDR
pathogens with cases of VAP caused by non-MDR
pathogens, does not allow for organism-related conclusions.
Regarding the potential therapy-related causes for poor
outcomes - inferior antibiotics and delay in effective therapy -
here too Depuydt and colleagues’ study does not allow for
comparison, because its definition of effective therapy does
not account for treatment that is microbiologically effective
but clinically problematic. Take, for example, a patient with
VAP caused by methicillin-susceptible Staphylococcus
aureus who is treated with vancomycin rather than an anti-
staphylococcal beta-lactam agent. According to the study
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definitions, this patient received appropriate therapy, even
though the beta-lactam is the superior drug. An even more
extreme case would be if the patient were treated with
daptomycin, an agent to which almost all isolates of S. aureus
are susceptible, but that failed in a clinical trial of pneumonia
treatment, likely due to inhibition by pulmonary surfactant [6].
Similarly, a patient with VAP caused by an extended-
spectrum beta-lactamase-producing, gentamicin-susceptible
pathogen, who received ceftazidime and gentamicin as
empiric therapy at diagnosis of VAP, would also be con-
sidered to have received appropriate therapy according to
the study definitions, although an aminoglycoside as mono-
therapy for pneumonia would not be considered clinically
appropriate.
In the study, 37% of patients with VAP caused by MDR
pathogens died within 30 days, versus 20% of patients with
non-MDR VAP, a statistically significant difference (p = 0.02).
The significance of MDR etiology is not sustained in
multivariable analysis, leading the authors to conclude that
MDR etiology is not an independent risk factor for mortality in
VAP. Almost all patients in the MDR group received therapy
considered appropriate according to the study definitions
(79% by 24 hours and 87% by 48 hours). We therefore have
only limited ability to determine the impact of resistance on
mortality insofar as it causes delay in effective therapy.
Although there were no differences between survivors and
non-survivors in receipt of appropriate therapy at either 24 or
48 hours in this study, other studies, including a meta-
analysis, have demonstrated such a difference [7]. Yet in the
absence of data to distinguish between therapy that is
clinically appropriate and therapy that is microbiologically
sound but clinically problematic, the effect on mortality of
delay in receiving truly appropriate therapy, and the potential
impact of this delay on the results of the multivariable
analysis, remain unknown.
As there is no ethically tenable way to compare outcomes of
untreated MDR and non-MDR infection, studies that attempt
to isolate the specific impact of resistance on outcome of
infection cannot do so divorced from consideration of the
effect of the therapy received. In addition to assessing delay
in institution of therapy, analysis of the effect of appropriate-
ness of therapy must take into account such issues as tissue
penetration, pharmacokinetic and pharmacodynamic proper-
ties of the agent used, antimicrobial activity at varying pH, and
correctness of dosing and intervals of administration.
The outcomes study by Depuydt and colleagues, like others
before it, addresses the question of the impact of resistance
without dissecting fully the issue of appropriateness of
therapy received. Future outcomes studies relating to
infections with MDR pathogens must delve more deeply into
this area in order to yield results that are less potentially
confounded. Until such analyses are performed, we should
consider the question of the impact of resistance on
outcomes of bacterial infection as one for which more data
are needed, but be guided by the abundance of evidence
pointing toward a deleterious effect.
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